Ranibizumab was significantly more costly than bevacizumab for both continuous ( +14989 / patient ( $ 23468 ) ; 95 % CI 14522 to 15456 ; p < 0.001 ) and discontinuous treatment ( +8498 ( $ 13305 ) ; 95 % CI 7700 to 9295 ; p < 0.001 ) , with negligible difference in QALYs .